[CAS NO. 2760611-38-7] CYP4Z1-IN-1
PRODUCTS SPECIFICATIONS [2760611-38-7]
DESCRIPTION [2760611-38-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 250.29 |
| Molecular Formula | C13H18N2O3 |
| SMILES | O=C(CCCC1=CC=C(C=C1)N/C=N/O)OCC |
Summary
CYP4Z1-IN-1 (compound 7c) is a potent CYP4Z1 inhibitor, with an IC 50 of 41.8 nM. CYP4Z1-IN-1 decreases the expression of breast CSCs stemness markers, spheroid formation, and metastatic ability as well as tumor-initiation capability in a concentration-dependent manner in vitro and in vivo [1] .
IC50 & Target
|
CYP4Z1 41.8 ± 1.4 nM (IC 50 ) |
CYP4F11 291.3 ± 46 nM (IC 50 ) |
CYP4F12 1598.3 ± 5 nM (IC 50 ) |
CYP2D6 >10 000 nM (IC 50 ) |
CYP2C9 >10 000 nM (IC 50 ) |
||||
|
CYP3A4 >10 000 nM (IC 50 ) |
||||||||
In Vitro
CYP4Z1-IN-1 (compound 7c) shows antiproliferative activity against breast CSCs (cancer stem cells), with an
IC
50
of 483 ± 2.5 nM
[1]
.
CYP4Z1-IN-1 (0.8-51.2 μM, 24 h) suppresses the expression of stemness markers (P-gp, Oct3/4, Nanog, ALDH1A1, and Sox2) in breast cancer cells
[1]
.
CYP4Z1-IN-1 (0.8-51.2 μM, 24-48 h) attenuates the migration and invasion ability of breast cancer cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | MCF-7 and MDA-MB-231 cells |
| Concentration: | 0.8 μM, 3.2 μM, 12.8 μM, 51.2 μM |
| Incubation Time: | 24 h |
| Result: | Significantly suppressed the protein expression of stemness markers (P-gp, Oct3/4, Nanog, ALDH1A1, and Sox2) in MCF-7 cells in a concentration-dependent manner. |
In Vivo
CYP4Z1-IN-1 (compound 7c) (2000 mg/kg, orally, for 7 days) shows no evident toxicity and body weight loss in mice
[1]
.
CYP4Z1-IN-1 (MCF-7 and MDA-MB-231 cells (12.8 μM, 72 h) implanted in the inguinal mammary gland of mice subcutaneously) blocks the tumor-initiating ability of breast cancer cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Mice [1] |
| Dosage: | 2000 mg/kg |
| Administration: | orally, for 7 days |
| Result: | Showed that compound 7c was rather safe; no evident toxicity and body weight loss were observed. |
| Animal Model: | BALB/c-nude mice (3-4 week old, female) [1] |
| Dosage: | 12.8 μM |
| Administration: | MCF-7 and MDA-MB-231 cells were pre-treated with 7c (12.8 μM) for 72 h and were then implanted in the inguinal mammary gland of mice subcutaneously |
| Result: | Blocked the tumor-initiating ability of breast cancer cells. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.